Compare RDVT & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDVT | ASMB |
|---|---|---|
| Founded | 2017 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.9M | 440.0M |
| IPO Year | 2017 | 2010 |
| Metric | RDVT | ASMB |
|---|---|---|
| Price | $35.26 | $27.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $62.00 | $43.40 |
| AVG Volume (30 Days) | ★ 107.6K | 62.1K |
| Earning Date | 03-04-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 82.00 | ★ 91.78 |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $90,252,000.00 | N/A |
| Revenue This Year | $15.06 | N/A |
| Revenue Next Year | $15.07 | $274.75 |
| P/E Ratio | $39.87 | ★ N/A |
| Revenue Growth | ★ 20.03 | N/A |
| 52 Week Low | $32.23 | $7.76 |
| 52 Week High | $64.14 | $39.71 |
| Indicator | RDVT | ASMB |
|---|---|---|
| Relative Strength Index (RSI) | 30.13 | 44.15 |
| Support Level | N/A | $27.10 |
| Resistance Level | $52.43 | $30.66 |
| Average True Range (ATR) | 2.06 | 1.30 |
| MACD | -0.42 | -0.05 |
| Stochastic Oscillator | 6.28 | 9.15 |
Red Violet Inc builds proprietary technologies and applies analytical capabilities to deliver identity intelligence. The company's solutions enable the real-time identification and location of people, businesses, assets, and their interrelationships. These solutions are used for purposes including identity verification, risk mitigation, due diligence, fraud detection and prevention, regulatory compliance, and customer acquisition. Its cloud-native, AI-enabled identity intelligence platform, CORE, is purpose-built for the enterprise, yet flexible enough for organizations of all sizes, bringing clarity to massive datasets by transforming data into intelligence. The company generates substantially all of its revenue from licensing its solutions.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.